173 related articles for article (PubMed ID: 10399376)
1. [The concomitant presence of prohemorrhagic and thrombophilic changes in coagulation factor V: a severe defect of coagulant activity and homozygote resistance to activated protein C].
Rossi V; Di Rocco N; Del Sonno C; Crivelli S
Ann Ital Med Int; 1999; 14(2):127-9. PubMed ID: 10399376
[TBL] [Abstract][Full Text] [Related]
2. [Activated protein C resistance--a recently discovered hereditary thrombophilia].
Moland L; Sandset PM
Tidsskr Nor Laegeforen; 1998 Sep; 118(23):3590-5. PubMed ID: 9820002
[TBL] [Abstract][Full Text] [Related]
3. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
[TBL] [Abstract][Full Text] [Related]
4. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of thrombophilia based on coagulation and genetic studies].
Bałszan-Kowalska I
Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C (APC) resistance: considerations about the importance of using the original and modified methods in thrombophilic disease.
Gennari L; Blanco AN; Bermejo E; Salviú J; Grosso S; Lazzari MA
Thromb Haemost; 2000 Jul; 84(1):138-9. PubMed ID: 10928486
[No Abstract] [Full Text] [Related]
7. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Payzin B; Adakan FY; Yalçin HC; Cetinkaya GS; Berkmen S; Eraslan S; Unsal B
Turk J Gastroenterol; 2006 Sep; 17(3):183-90. PubMed ID: 16941251
[TBL] [Abstract][Full Text] [Related]
8. Thrombophilic markers in patients with congenital bleeding disorders.
Vezendi K; Tápai K; Erdödi E; Szabó I; Tomek A; Oszlács J; Scheibl E
Haematologia (Budap); 2002; 32(4):467-73. PubMed ID: 12803120
[TBL] [Abstract][Full Text] [Related]
9. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM
Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310
[TBL] [Abstract][Full Text] [Related]
10. In the presence of other inherited or acquired high-risk situations, the FV Cambridge mutation may be an additional thrombophilic risk factor, through its effect on APC sensitivity.
Santacroce R; Bossone A; Brancaccio V; Fortina P; Margaglione M
Thromb Haemost; 2000 Jun; 83(6):963-4. PubMed ID: 10896257
[No Abstract] [Full Text] [Related]
11. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
Mikovic D; Rakicevic L; Kovac M; Radojkovic D
Thromb Haemost; 2000 Oct; 84(4):723-4. PubMed ID: 11057877
[No Abstract] [Full Text] [Related]
12. [National evaluation of the diagnosis of activated protein C resistance].
Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R
Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
14. Screening for inherited thrombophilia: indications and therapeutic implications.
De Stefano V; Rossi E; Paciaroni K; Leone G
Haematologica; 2002 Oct; 87(10):1095-108. PubMed ID: 12368166
[TBL] [Abstract][Full Text] [Related]
15. Association of factor V deficiency with factor V HR2.
Faioni EM; Castaman G; Asti D; Lussana F; Rodeghiero F
Haematologica; 2004 Feb; 89(2):195-200. PubMed ID: 15003895
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
Fábregues F; Tàssies D; Reverter JC; Carmona F; Ordinas A; Balasch J
Fertil Steril; 2004 Apr; 81(4):989-95. PubMed ID: 15066453
[TBL] [Abstract][Full Text] [Related]
18. [APC resistance--most frequent familial thrombophilia].
Herren S; Lämmle B
Ther Umsch; 1999 Sep; 56(9):499-501. PubMed ID: 10517118
[TBL] [Abstract][Full Text] [Related]
19. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
Rolla R; Vidali M; Meola S; Pollarolo P; Pergolini P; Bellomo G
Clin Lab; 2011; 57(9-10):711-7. PubMed ID: 22029186
[TBL] [Abstract][Full Text] [Related]
20. Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family.
Santamaría A; Soria JM; Tirado I; Mateo J; Coll I; Souto JC; Fontcuberta J
Thromb Haemost; 2005 Jun; 93(6):1193-5. PubMed ID: 15968408
[No Abstract] [Full Text] [Related]
[Next] [New Search]
